Title Production and Prophylactic Efficacy Study of Human Papillomavirus-like Particle Expressing HPV16 L1 Capsid Protein
Author Jie-Yun Park 1 , Hyun-Mi Pyo 1 , Sun-Woo Yoon 1 , Sun-Young Baek 2 , Sue-Nie Park 2 , Chul-Joong Kim 3 and Haryoung Poo 1 *
Address 1 Korea Research Institute of Bioscience and Biotechnology, Daejon 305-333, Korea; 2 Korea Food and Drug Administration, Seoul 122-704, Korea; 3 Choongnam University, Daejon 305-764, Korea
Bibliography Journal of Microbiology, 40(4),313-318, 2002,
Key Words Human papillomavirus (HPV), capsid protein, hemagglutination inhibition
Abstract To perform the prophylactic study of a vaccine derived from human papillomavirus (HPV) using Balb/c mice, we produced virus like particles consisting of HPV capsid protein L1 which has been reported to induce significant humoral and cellular immunity using various animal model systems. In order to produce HPV16 VLPs, the cDNA of L1 capsid protein in HPV type 16, obtained by polymerase chain reaction, was inserted into yeast expression vector, YEG[alpha]-HIR525 under the control of GAL10 promoter. The transformation of YEG[alpha]-HPV16 L1 was performed into the yeast Saccharomyces cerevisiae Y2805 by the lithium acetate method and the yeast clone expressing the highest level of L1 capsid protein of human papillomavirus type 16 was selected by Western blot analysis using anti-HPV16 L1 antibody. The purification of HPV16 VLP has been performed by the ultracentrifugation and gel-filtration methods. To validate the vaccine efficacy of the purified HPV16 VLPs and investigate the properties of HPV16 VLPs to induce humoral immunity, ELISA assay was performed. A significantly increased production of anti-HPV16 VLP antibodies was observed in sera from immunized mice. The neutralization activity of antibodies in the sera from the vaccinated mice was demonstrated by a rapid and simple assay to detect hemagglutihation inhibition activity
Download PDF 404-13.pdf